牛牛AI助理已提取核心訊息
Michael Joseph Golembiewski, the Chief Financial Officer of Seelos Therapeutics, Inc. (SEEL), completed a purchase of 417 shares of common stock on February 29, 2024. The transaction was carried out directly with shares acquired at a price of $1.097 each. Following this transaction, Golembiewski's direct holdings in the company increased to a total of 86,869 shares. The acquisition reflects a transaction value of approximately $457.37, reinforcing the CFO's investment in the company's equity.
Michael Joseph Golembiewski, the Chief Financial Officer of Seelos Therapeutics, Inc. (SEEL), completed a purchase of 417 shares of common stock on February 29, 2024. The transaction was carried out directly with shares acquired at a price of $1.097 each. Following this transaction, Golembiewski's direct holdings in the company increased to a total of 86,869 shares. The acquisition reflects a transaction value of approximately $457.37, reinforcing the CFO's investment in the company's equity.
Seelos Therapeutics, Inc.（SEEL）首席財務官邁克爾·約瑟夫·戈倫比耶夫斯基於2024年2月29日完成了對417股普通股的購買。該交易直接進行，以每股1.097美元的價格收購了股票。在這筆交易之後，戈倫比耶夫斯基在該公司的直接持股量增加到總共86,869股。此次收購反映了約457.37美元的交易價值，加強了首席財務官對公司股權的投資。
Seelos Therapeutics, Inc.（SEEL）首席財務官邁克爾·約瑟夫·戈倫比耶夫斯基於2024年2月29日完成了對417股普通股的購買。該交易直接進行，以每股1.097美元的價格收購了股票。在這筆交易之後，戈倫比耶夫斯基在該公司的直接持股量增加到總共86,869股。此次收購反映了約457.37美元的交易價值，加強了首席財務官對公司股權的投資。
有用
沒用